ASM set a 2030 course—>€5.7bn revenue, 30% margins—built on ALD dominance, growing epi, outcome-based services and sustainability that lowers customers’ total costs.
Positive evERA data make giredestrant a real contender in HR+/HER2– breast cancer. Late-line use points to ~$1B peak; earlier-line wins could multiply that.
At a Baird investor event, Alcon CEO David Endicott framed the next 24–36 months as “dynamic” but messy: seven launches in flight, five acquisitions in ~18 months, and a full-fleet refresh anchored by the new Unity platform. The company intends to replace its ~30,000 installed cataract/refractive systems
Align Technology Inc., the maker of Invisalign clear aligners, stunned investors late Wednesday after it lowered its full-year outlook and unveiled a restructuring that includes layoffs and factory write-downs.
Schindler’s self‑help program is delivering
Swiss chocolatier Barry Callebaut (BARN) reported its third revision to full-year volume expectations, citing extreme volatility in cocoa prices, as unveiled in its nine‑month results today. The company now anticipates a 7 % drop in sales volume by Aug. 31—an increase from the earlier forecast of a mid‑single‑
The U.S. Commerce Department has rescinded the licence letters it sent in late May that forced America’s three big electronic-design-automation vendors—Synopsys, Cadence Design Systems and Siemens EDA—to halt most sales and support for Chinese chip designers. The companies say the notice arrived on 2 July and
Micron Q3 Earnings Call
Showing 12 of 8 total posts
Stay up to date with curated collection of our top stories.
